India, July 30 -- Teva Pharmaceutical Industries Ltd (TEVA) reported Wednesday a profit in its second quarter, compared to prior year's loss, with slightly higher net revenues. Adjusted earnings beat market estimates, while top line missed the view.
Further, the company raised the lower end of its fiscal 2025 adjusted earnings outlook range, and maintained revenue view. The company added that it is on track for 30 percent operating profit margin by 2027 in line with Pivot to Growth Strategy.
In the pre-market activity, Teva shares were losing around 2 percent to trade at $16.21.
For fiscal 2025, the company now projects adjusted earnings in a range of $2.50 to $2.65 per share, a growth of $0.05 at the low-end of its previous outlook rang...